Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/8565
Title: | A review of the International Early Recommendations for Departments Organization and Cancer Management Priorities during the Global COVID-19 Pandemic. Applicability in Low- and Middle-Income Countries | Authors: | Belkacemi, Yazid Grellier, Noemie Ghith, Sahar Debbi, Kamel Coraggio, Gabriele Bounedjar, Adda Samlali, Redouane Tsoutsou, Pauletta G. Ozsahin, Mahmut Chauvet, Marie-Pierre Turkan, Sedat Boussen, Hamouda Kuten, Abraham Tesanovic, Dusanka Errihani, Hassan Benna, Farouk Bouzid, Kamel Idbaih, Ahmed Mokhtari, Karima Popovic, Lazar Spano, Jean-Philippe Lotz, Jean-Pierre Cherif, Aziz To, Hahn Kovcin, Vladimir Arsovski, Oliver Beslija, Semir Dzodic, Radan Markovic, Ivan Vasovic, Suzana Stamatovic, Liljana Radosavljevic, Davorin Radulovic, Sinisa Vrbanec, Damir Sahraoui, Souha Vasev, Nino Stojkovski, Igor Risteski, Milan Freixa, Salvador Villà Krengli, Marco Radosevic, Nina Mustacchi, Giorgio Filipovic, Mladen Kerrou, Khaldoun Taghian, Alphonse G. Todorovic, Vladimir Geara, Fady Gligorov, Joseph |
Keywords: | COVID-19 oncology radiotherapy |
Issue Date: | Jun-2020 | Publisher: | Elsevier BV | Journal: | European Journal of Cancer | Abstract: | Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low and middle income countries (LMICs). In this review we aimed to summarize these international guidelines according to cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumor criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints | URI: | http://hdl.handle.net/20.500.12188/8565 | DOI: | 10.1016/j.ejca.2020.05.015 |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.